TRANSDERMAL THERAPEUTIC SYSTEM FOR TRANSDERMAL ADMINISTRATION OF GUANFACINE CONTAINING AT LEAST ONE EXCIPIENT Russian patent published in 2024 - IPC A61K9/70 A61K31/165 A61K47/30 A61K47/10 A61P25/00 

FIELD: pharmaceuticals.

SUBSTANCE: group of inventions relates to a transdermal therapeutic system and its use. A transdermal therapeutic system (TTS) for transdermal administration of guanfacine, comprising a guanfacine-containing layered structure, wherein the said guanfacine-containing layered structure comprises the following: A) substrate; and B) guanfacine-containing layer; wherein the transdermal therapeutic system contains at least one polymer selected from the group consisting of silicones, acrylates, silicone-acrylic hybrid polymers, polyisobutylenes and styrene-isoprene-styrene block copolymers, and at least three excipients, where the first excipient is a polyoxyethylene lauryl ether, which is present in an amount of 1–10% by weight based on the total weight of the guanfacine-containing layer, the second excipient is oleyl alcohol, which is present in an amount of 1–10% by weight based on the total weight of the guanfacine-containing layer, and the third excipient is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, which is present in an amount of 0.5–10% by weight, based on the total weight of the guanfacine-containing layer. Use of a transdermal therapeutic system in a method of treating hypertension or attention deficit hyperactivity disorder (ADHD) and/or as adjunctive therapy to stimulant medications in human patients aged 6–17 years.

EFFECT: above-described group of inventions provides a sufficient rate of percutaneous penetration to achieve a therapeutically effective dose of the active component.

11 cl, 11 dwg, 24 tbl, 12 ex